disease-modifying treatment

I’ve been on the same disease-modifying therapy (DMT), Gilenya (fingolimod), for my multiple sclerosis (MS) for several years. It’s worked well for me, as my last exacerbation was at least five years ago. I credit this DMT for stabilizing my MS and allowing me to live better with my…

People with multiple sclerosis (MS) in the United Kingdom are less likely to be on disease-modifying treatments (DMTs) compared with MS patients in other countries in Europe, a new study reports. “We know that getting early treatment with disease-modifying MS therapies can improve long term health and wellbeing.

Treatment with interferon beta (IFN-beta) — a disease-modifying therapy that lowers inflammation in multiple sclerosis (MS) — was found to restore the ability of blood vessels in the brain to dilate following a stimulus. A new study suggests that this ability, called cerebrovascular reactivity or CVR, is reduced…

Exercise prior to being diagnosed with multiple sclerosis (MS) was associated with less depression and anxiety among patients, likely due to a reduction in the levels of an inflammatory molecule called interleukin-2 (IL-2), a study revealed. “This finding supports the notion that exercise in the early stages may act…

A program aimed at optimizing the use of highly effective therapies successfully lowered treatment costs and relapse rates among people with multiple sclerosis (MS) in Southern California, according to a study. “Our novel physician-led approach simultaneously reduced MS DMT [disease-modifying therapy] expenditures and the frequency of MS relapses. We…

Tecfidera has a lower risk of discontinuation due to treatment failure than Aubagio in people with multiple sclerosis (MS), a new observational study in Norway suggests. In the study, people receiving Tecfidera (dimethyl fumarate) were 38% less likely to experience treatment failure and stop use than those receiving…

High levels of kappa-free light chains, or kappa-FLC, in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — may help identify people with clinically isolated syndrome (CIS) who will progress sooner to multiple sclerosis (MS), a study reports. Overall, those with a high…

People with  multiple sclerosis (MS) who are using a disease-modifying therapy — and are at a younger age — when they have a relapse within the first three years of their disease course are more likely to recover completely, lowering their risk of long-term, 10-year disability, a study suggests. Complete recovery…

Concerns about COVID-19 caused people with multiple sclerosis (MS) to postpone or deviate from recommended care — including appointments, imaging scans, and laboratory tests, a survey found. But notably, while most patients perceived their disease-modifying therapies as an added risk factor…

People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of disease-modifying treatments (DMTs) some 20 years ago, according to a retrospective study. The study, “Outcomes in a Modern Cohort of Treated Multiple Sclerosis Patients Followed from Diagnosis Up…

Women diagnosed with multiple sclerosis (MS) say they lack guidance regarding family planning, pregnancy, and breastfeeding, according to a survey. Sixteen percent of those women also reported they didn’t become pregnant due to MS-related concerns. Casey E. Engel,  clinical researcher at Weill Cornell Medical College in New York,  presented the…

Sanofi Genzyme‘s Lemtrada (alemtuzumab) and Biogen’s Tysabri (natalizumab) are more effective in preventing conversion to secondary progressive multiple sclerosis (SPMS) compared to older injectable drugs, researchers from the University of Cambridge in the U.K. reported at the 7th Joint ECTRIMS-ACTRIMS Meeting Oct. 25-28 in Paris. The…

Ocrevus (ocrelizumab), a recently approved therapy for relapsing and primary progressive multiple sclerosis (MS), is now on the U.S. market, but research into its use is far from over. Several clinical trials, sponsored by Ocrevus’ developer Genentech or its parent company Roche, are looking at various aspects of the treatment. Multiple Sclerosis…

Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely discontinue their treatments, Canadian researchers at Vancouver’s University of British Columbia argue. Their Sanofi Genzyme-sponsored study, “When Should Disease-Modifying Treatments Be Discontinued in Patients with Multiple Sclerosis: An…

A Phase 3 clinical trial exploring Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) is now recruiting participants. The trial, sponsored by Genentech (NCT02637856), is seeking patients who have previously taken a disease-modifying treatment that did not adequately control their disease activity. Participants must be between 18 and 55…

A major dilemma facing clinicians is whether to continue treatment with disease-modifying drugs, effective in relapsing-remitting multiple sclerosis (RRMS), as the disease progresses to secondary progressive MS (SPMS). In SPMS,  these treatments seem to lose their benefits and — as they are often associated with severe side effects and high costs — clinicians…